A shbaugh and colleagues (1) first described a syndrome of acute respiratory distress in adults that closely resembled respiratory distress in infants in 1967. They detailed the clinical course of 12 patients treated in Denver for respiratory failure that did not respond to usual therapeutic modalities of 272 patients receiving respiratory support. These patients had acute onset of tachypnea, hypoxemia, panlobular infiltrates on chest radiography, and loss of lung compliance. These early investigators thought this syndrome was a result of a deficiency in surfactant and found positive endexpiratory pressure helpful in treating the atelectasis and hypoxemia. They also thought that corticosteroids were helpful for patients with the syndrome as a result of fat embolism. In 1971 these same investigators coined the name Adult Respiratory Distress Syndrome (ARDS) (2).
Since this initial description in 1967, ARDS has been the focus on intense scrutiny and attempts to improve the outcome. The European-American Consensus Committee on ARDS was formed to develop a uniform definition for ARDS to aid clinical trial design (3). The conference investigators agreed that ARDS is the severe form of an acute lung injury (ALI) and recommended that the syndrome be called the "acute respiratory distress syndrome" (ARDS) rather than "Adult Respiratory Distress Syndrome." As such, they defined ALI and ARDS as follows: a) acute onset; b) bilateral infiltrates on chest radiograph; c) hypoxemia; and d) no evidence of left atrial hypertension (pulmonary artery occlusion pressure Յ18 torr). The degree of hypoxemia is more severe in ARDS and is defined as a PaO 2 /FIO 2 ratio Յ200 torr whereas a PaO 2 /FIO 2 ratio Յ300 torr is defined as ALI. The severity of ARDS can be scored (Murray lung injury score, LIS) using several easily measured clinical variables (Table 1 ) (4). ARDS is an entity that occurs in various clinical settings, including sepsis syndrome, multiple emergency transfusions, near-drowning, and multiple trauma, including pulmonary contusion, pancreatitis, and aspiration of gastric contents. Excellent recent reviews of the pathophysiology of ARDS are available (5-8). The mortality rate of ARDS remains high but outcome has improved over the last decade (mortality, 45% to 92%) (9 -19). Numerous therapeutic approaches have been investigated in an attempt to alter the course of ARDS. No therapeutic interventions have convincingly altered the underlying pathophysiology of ARDS. Therefore, treatment remains essentially supportive. In this review, we will evaluate prospective, randomized trials (PRT) of therapies for ARDS. Throughout this review, therapies are evaluated by the quality of the evidence to support their use and recommendations are made according to this evidence (Table 2) .
Ventilation Management
Mechanical ventilation is a lifesaving therapeutic intervention in patients with ARDS. However, many clinicians are concerned that it may exacerbate lung injury in patients with acute respiratory failure. Further, ongoing inflammation in the lung from mechanical ventilation may contribute to multiple organ failure (20) . Numerous animal studies suggest that mechanical ventilation can cause damage to normal lungs or increase damage to injured lungs. This ventilation-derived lung injury is functionally and histologically similar to ARDS (21-31). Injury may occur from increased airway pressure with regional overdistension of alveoli or the repeated opening and closing of small airways with resultant shear forces. Work by Gattinoni et al. (32) suggests the lung may be separated into thirds in ARDS:
one third is consolidated and does not participate in ventilation, one third is overdistended forming bullae, and the last third has a relatively normal ventilation-perfusion relationship. Thus, the hypothesis is that the lung is not uniformly stiff in ARDS; rather, there is a reduced amount of normal lung tissue, referred to as a "baby lung." Ventilation with high airway pressures or volumes favors delivery of a disproportionate share of tidal volume to the ventilated small lung, resulting in overdistension and damage.
Noninvasive Positive Pressure Ventilation
Invasive mechanical ventilation is associated with a variety of complications. Innovations in noninvasive positive pressure ventilation (NPPV) may avoid endotracheal intubation and lead to a decrease in morbidity (33, 34). The most common use of NPPV has been in chronic respiratory failure from neuromuscular disease and chronic obstructive pulmonary disease. Most studies of NPPV have been case series or compare NPPV and historical controls. There is little data from PRT. Variables that may affect the success of NPPV include severity of disease, type of patient, mask (nasal or face), mode (pressure or volume preset), and patient compliance. The highest success rates are seen in patients with hypercapnic respiratory failure and are more limited in acute hypoxemic failure. Contraindications to NPPV include hemodynamic instability, uncontrolled arrhythmias, inability to control airway, high aspiration risk, inability to clear secretions, inability to fit the mask, gastrointestinal bleeding, and a poorly compliant patient. Complications include skin necrosis, gastric distention, aspiration, conjunctivitis, and pneumothorax.
There is little controlled data on NPPV in ALI/ARDS (33, 34). The most common indication for NPPV has been in patients with acute hypercapnic respiratory failure, especially chronic obstructive pulmonary disease. In a small randomized trial of NPPV in patients without chronic obstructive pulmonary disease (n ϭ 41 patients), Wysocki et al. (35) found that patients with acute hypoxemic respiratory failure do not receive the same benefit from NPPV as patients with hypercapnia. In two small series of 11 and 12 patients, NPPV avoided intubation in 14 of 20 patients receiving NPPV as a primary therapy (36, 37). Thus, small series suggest that NPPV may avoid intubation in some patients. However, these studies only constitute level 2 and 4 data and NPPV can only be given a Grade C recommendation.
Lung Protective Ventilation
"Permissive hypercapnia" was introduced in 1990 as a strategy of mechanical ventilation to limit tidal volume and airway pressure while disregarding hypercapnia to avoid lung injury (38). In one uncontrolled study of 53 patients with severe ARDS, the hospital mortality rate was significantly lower than that predicted by the Acute Physiology and Chronic Health Evaluation II scores (26.4% vs. 53.3%, p ϭ .004) (39). The mortality rate increased with increasing number of organ failures, but was only 43% in patients with Ն4 organ failures, 20.5% with Ն3 organ failures, and 6.6% with respiratory failure only. This outcome was achieved despite a mean maximum PaCO 2 of 66.5 torr (range, 38 -158 torr) and a mean arterial pH at the same time of 7.23 (range, 6.79 -7.45). Deleterious effects of hypercapnia include increase in pulmonary arterial pressure (40), impaired cardiac contractility, cardiac arrhythmias, impaired renal perfusion, and increase in intracranial hypertension. However, several uncontrolled trials confirm that the technique of permissive hypercapnia is safe and leads to reasonable outcomes (41, 42 ). An adjuvant technique to avoid hypercapnia with this ventilation strategy is to flush the CO 2 out of the dead space with tracheal gas insufflation (43-45).
One randomized study of low tidal volume (V T ϭ 6 mL/kg) vs. standard tidal PEEP, positive end-expiratory pressure. The final value is obtained by dividing the sum of the individual component scores by 4. Scores: 0, no injury; 0.1-2.5, mild to moderate injury; Ͼ2.5, severe injury (acute respiratory distress syndrome). Reprinted with permission (4). volume (V T ϭ 12 mL/kg) in all ventilated patients in a surgical intensive care unit (ICU) found decreased morbidity in the low tidal volume group (46). The incidence of pulmonary infection tended to be lower and duration of intubation and hospital stay tended to be shorter for nonneurosurgical and noncardiac surgical patients randomized to low V T . The use of low V T was associated with a statistically significant but clinically irrelevant decrease in oxygenation. Four recent multicenter studies have compared limited volume and pressure ventilation (V T Ͻ8 mL/kg or peak inspiratory pressure Ͻ30 cm H 2 O) to a strategy with conventional ventilation (V T of 10 -15 mL/kg or peak inspiratory pressure Ͻ50 cm H 2 O) (47-50). In the study by Stewart et al. (47) , 120 patients at high risk for ARDS had a mortality of 50% in the limited-ventilation group and 47% in the control group (Tables 3 and 4 ). In the study by Brochard et al. (51), a total of 116 patients with ARDS and no organ failure other than the lung were enrolled in 25 centers. Mortality at day 60 (low V T 46.6% vs. control 37.9%, p ϭ .38), duration of mechanical ventilation (23.1 vs. 21.4 days, p ϭ .85), the prevalence of pneumothorax (14% vs. 12%, p ϭ .78), and the secondary occurrence of multiple organ failure (41% vs. 41%, p ϭ 1) were also not affected by ventilation strategy. Brower et al. (49) found no significant differences in requirements for positive end-expiratory pressure or FIO 2 , fluid intakes/outputs, requirements for vasopressors, sedatives, or neuromuscular blocking agents, percentage of patients who achieved unassisted breathing, ventilator days, or mortality (Table 3) . Ranieri et al. (50) examined the effect on protective ventilation on plasma and bronchoalveolar lavage concentrations of inflammatory mediators including interleukin (IL)-1␤, IL-6, IL-1 receptor antagonist, tumor necrosis factor (TNF)-␣, and TNF-␣ receptors. Patients in the lungprotective strategy group had a reduction in bronchoalveolar lavage concentrations of polymorphonuclear cells, TNF-␣, IL-1␤, soluble TNF-␣ receptor 55, and IL-8, and in plasma and bronchoalveolar lavage concentrations of IL-6, soluble TNF-␣ receptor 75, and IL-1 receptor antagonist (50).
An alternative lung protective ventilation strategy is the "open lung" technique championed by Amato et al. (52, 53 ). This technique is aimed at maintaining a level of positive end-expiratory pressure above the level at which alveoli collapse, clinically defined as the "inflection point" in a lung pressure-volume curve, and limiting distending pressure and volume. A total of 53 patients with early acute respiratory distress syndrome were randomized to receive conventional or protective mechanical ventilation (Table 3) . Protective ventilation involved end-expiratory pressures above the lower inflection point on the static pressure-volume curve, a tidal volume of Ͻ6 mL per kilogram, driving pressures of Ͻ20 cm of water above the positive end-expiratory pressure value, permissive hypercapnia, and preferential use of pressure-limited ventilator modes. In the protective-ventilation group, the 28-day mortality was 38% as compared with 71% in the conventional-ventilation group (p Ͻ .001) (Fig. 1) . The rates of weaning from mechanical ventilation were 66% in the protective-ventilation group and 29% in the conventional ventilation group (p ϭ .005). Clinical barotrauma occurred in 7% and 42% of patients in the protective and control ventilation groups respectively (p ϭ .02). However, protective ventilation was not associated with a higher rate of survival to hospital discharge (45 vs. 71%, p ϭ .37). There are several concerns about the results of this study. As with the Stewart et al. (47) study from Canada, the plateau pressure in the conventional ventilation group was Ͻ40 cm H 2 O (mean, 37.8 cm H 2 O) during the first week of ventilation. Thus, one can argue that the conventional ventilation group was also ventilated with a protective strategy. Additionally, the mortality rate in the control group was very high at 71%, raising concern about potentially preventable deaths (54). On the other hand this figure is not out of line with other published data on the mortality of ARDS (10, 19). The study was relatively small, enrolling only 53 patients over 4.5 yrs of 270 patients identified with ARDS.
However, the most definitive support for low volume/pressure ventilation has come from the National Institutes of Health (NIH) ARDS Network trial comparing 6 mL/kg vs. 12 mL/kg V T in patients with ALI and ARDS (55, 56). The NIH ARDS Network is a clinical trial consortium of 10 clinical centers including 24 hospitals. For details of the Network as well as trial methodology, see www. ardsnet.org. The Data Safety and Monitoring Board stopped the trial early after a planned data analysis. There were 432 patients enrolled into the 6 mL/kg arm and 429 into the 12 mL/kg group. Mean tidal volume in the lower stretch group was 6.2 Ϯ 0.8 mL vs. 11.8 Ϯ 0.8 mL in the traditional group. Mean end-expiratory plateau pressures were 25 Ϯ 6 and 33 Ϯ 8 cm H 2 O, and the mortality before discharge in the two arms was 31.3% and 39.8% respectively (p ϭ .01) ( Table 3 ). The mean number of days alive and off mechanical ventilation was 11.5 Ϯ 10.1 in the 6 mL/kg group vs. 9.9 Ϯ 10.2 in the 12 mL/kg group (p ϭ .03). There were no differences in the number of days that patients were receiving neuromuscular blocking agents between the two groups. Plasma IL-6 levels were not different between the two groups on day 0; but the decrease in the IL-6 between days 0 and 3 was greater in the lower tidal volume group. Collectively, these studies are strong support for the use of low volume/ pressure ventilation in ALI and ARDS. 
Inverse Ratio Ventilation
Normally, the ratio of time for inspiration to expiration (inspiratory:expiratory ratio, I:E) is 1:2 to 1:4. Inverse ratio ventilation (IRV) is a ventilator method that uses an extended inspiratory time with an I:E ratio Ͻ1:1 (typically 2:1). IRV can be performed with volume control ventilation with an end-inspiratory pause or a slow, decelerating flow rate or pressure control ventilation (PC-IRV) with a long inspiratory time. Theoretically, IRV leads to an increased mean airway pressure with a reduction in the shunt fraction at lower levels of positive endexpiratory pressure and peak alveolar pressure (57). Sustained elevations of airway pressure can recruit collapsed lung and lead to a decrease in dead space ventilation by facilitating mixing of gas, thus improving PaCO 2 levels or allowing a reduction in minute ventilation (V E ). On the other hand, some authors believe that the only mechanism of improving arterial oxygenation with IRV is by an increase in intrinsic positive end-expiratory pressure (58). Several trials have compared controlled ventilation and IRV while maintaining a constant positive end-expiratory pressure in a crossover trial design (59 -64). In sum, these trials demonstrate the following: a) oxygenation is primarily determined by mean airway pressure; b) applied positive end-expiratory pressure with controlled ventilation results in a similar or better improvement in oxygenation compared with IRV; c) IRV leads to a small reduction in PaCO 2 ; d) autopositive end-expiratory pressure leads to a significant reduction in cardiac output and systemic oxygen delivery. Complications of this form of ventilation include gas trapping with excessive intrinsic or auto-positive end-expiratory pressure, pneumothorax, cardiovascular compromise, and an increase in necessity for sedation. Excessive auto-positive endexpiratory pressure can lead to increased peak alveolar pressure or decreased V T , depending on the mode of ventilation (volume vs. pressure respectively).
The only studies to examine the effect of IRV on outcome have used historical controls as a comparison group. Abel et al. (65) compared 41 patients treated from 1990 -1993 using a variety of ventilation strategies to 78 patients using PC-IRV from 1993-1997. The use of PC-IRV was associated with a reduction in mortality from 66% to 34%. Despite the fact that the two groups of patients were well matched in case mix and disease severity, the authors correctly point out that factors other than ventilator strategy may account for the observed reduction in mortality. Similarly Papadakos et al. (66) reported a mortality rate of 10% in 30 surgical patients with ARDS treated with PC-IRV. As of yet, no PRT has been conducted to determine the effect of IRV compared with conventional ventilation on outcome in ARDS. Thus, the level of evidence in support of its use is Level 3 and 4. Thus, IRV receives a grade D recommendation.
Extracorporeal Life Support
Extracorporeal life support (ECLS) in ARDS is based on the concept that lung rest will improve recovery and ultimately survival. Extracorporeal support can be performed using high-flow veno-arterial bypass mainly for improved oxygenation (commonly referred to as extracorporeal membrane oxygenation, ECMO) or low flow veno-venous bypass mainly for CO 2 removal (extracorporeal CO 2 removal In 1974 the National Heart, Lung, and Blood Institute sponsored a prospective, randomized multicenter trial of ECMO with controlled ventilation compared with controlled ventilation alone (17). Patients were selected based on gas exchange. Fast entry was for PaO 2 Ͻ50 torr for Ͼ2 hrs on FIO 2 1.0 and positive endexpiratory pressure Ն5 cm H 2 O, whereas slow entry was for PaO 2 Ͻ50 torr for Ͼ12 hrs on FIO 2 0.6 and positive end-expiratory pressure Ն5 cm H 2 O after 48 hrs of therapy. Survival was only 10% in both the ECMO and conventional ventilation group. Potential explanations for the lack of efficacy may be that the positive pressure ventilation in the ECMO group was the same as in the conventional arm, the ECMO was done using veno-arterial bypass, and there was a very high complication rate (mainly bleeding). A second PRT of ECLS utilized PC-IRV with extracorporeal CO 2 removal in ARDS (78). A total of 40 patients were randomized using the same entry criteria as the NHLBI study. However, survival was not different (42% mechanical ventilation vs. 33% ECLS, p ϭ .8) Interestingly the overall survival of 38% was four times higher than the historical survival rate from the National Heart, Lung, and Blood Institute study (17) . Advocates of the technique point out that the techniques and results of ECLS have improved in recent years with a reduction in bleeding complications. With experienced centers reporting 46% to 66% survival compared with 10% survival in the NHLBI study, it is reasonable to consider a new PRT comparing a protocol using ECLS to standard controlled ventilation.
Prone Ventilation
Prone positioning to improve oxygenation in patients with ARDS was first proposed Ͼ20 yrs ago (79 -81). Improvement in oxygenation attributable to prone positioning may be a result of redistribution of ventilation or lung perfusion with improvement in matching because of improved dorsal lung ventilation (82). In the patient with ARDS in the supine position, ventilation is diverted to the nondependent lung region and the dependent region is likely to be consolidated (32). Perfusion of the dependent regions is also decreased because of hypoxic vasoconstriction as well as compression resulting from increased lung weight from edema. With the prone position, ventilation is more evenly distributed because of changes in gravitational distribution of pleural pressure and reduction of pleural pressure in the dorsal region of the lung (82, 83).
Numerous case series document that prone positioning improves arterial oxygenation in patients with ARDS (84 -94). These series consistently reveal that prone positioning results in an acute increase in arterial oxygenation in 60% to 92% of patients. The degree of improvement is variable. The response is difficult to predict, but in one series, responders had more severe hypoxemia, more hypercapnia, and a shorter elapsed time from the onset of ARDS until turning to the prone position (84). The improvement in oxygenation is usually not transient but oxygenation may return to baseline if the patient is turned back supine. A session of prone ventilation may last as long as oxygenation improves and the patient condition allows. Complications are infrequent but may include worsening oxygenation, skin pressure lesions, extubation, and catheter removal.
No PRT have been conducted on the effect of prone positioning on outcome in ARDS. One series of 20 patients treated in such a fashion had a mortality rate of only 10% (86). Stocker et al. (92) studied 25 patients with a lung injury score Ͼ2.5. Mean predicted mortality based on the Acute Physiology and Chronic Health Evaluation II score was 35.4%. Observed mortality was only 12%. These data are intriguing; however, these authors used a pressure limited ventilation strategy (peak inspiratory pressure Ͻ35 torr), which may explain in part the improvement in outcome. Prone ventilation cannot as yet be recommended as therapy for ARDS (Level 3 data, grade D recommendation), but the above experience does suggest that a PRT should be carried out.
Liquid Ventilation
Perfluorocarbons (PFC) are biologically inert compounds characterized by low surface tension, high density, and high respiratory gas solubility (95). Perfluorocarbons have been studied as either a sole method of ventilation or an adjunct to conventional gas ventilation. In total liquid ventilation, a volume of perfluorocarbon equal to lung functional residual capacity is instilled into the lung and to effect gas exchange, tidal volumes of perfluorocarbon are cycled with a specialized ventilator (95). In partial liquid ventilation (PLV), functional residual capacity of the lung is filled with perfluorocarbon as in total liquid ventilation, but tidal volume ventilation with gas is now performed with conventional mechanical ventilation (96). Partial liquid ventilation appears to be the more attractive of the two modalities given the limited cost and ease of application, less adverse effects on cardiac performance, pneumothorax, and bleeding (97). The benefits of PLV appear to result primarily from a reduction in alveolar surface tension, recruitment of additional lung tissue for ventilation, improvement in ventilation/perfusion mismatch, and lavage of cellular debris (98 -102). Not only is there a deficiency of surfactant in ARDS, it also appears to be dysfunctional. The resultant increases in surface tension favor alveolar collapse and decreased lung compliance. PFC, acting as a surfactant substitute, promotes re-expansion of atelectatic lung with improved compliance and gas exchange (100).
The perfluorocarbon is distributed primarily to the dependent regions of the lung, which are the regions of the lung characterized by atelectasis and consolidation in ARDS (103). Radiographs of patients undergoing PLV demonstrate a symmetric gravity-dependent distribution of the instilled perfluorocarbon, favoring the posterior lung relative to the anterior, nondependent lung (104). Influx of PFC into these consolidated regions increases intra-alveolar pressure, thus reducing pulmonary blood flow to the poorly ventilated, dependent lung. This effect redistributes blood flow to ventilated regions of lung resulting in improved ventilation-perfusion matching and reduction of physiologic shunt (98, 99, 101, 102). Histologic examination of lungs after PLV demonstrate a marked reduction in alveolar hemorrhage, lung fluid accumulation, and inflammatory infiltration relative to lungs from conventionally ventilated animals (98, 99, 105). The anti-inflammatory effects appear primarily attributable to the mechanical lavage of cellular debris from the lung by PFC (98, 99, 102). Increased intraalveolar pressure created by instillation of PFC appears to also reduce lung edema, alveolar macrophage, and neutrophil accumulation (105, 106). Further, Smith et al. (107) has shown a direct anti-inflammatory effect of PFC on alveolar macrophages in vitro.
Only two published adult trials of PLV in ARDS have been reported. Hirschl et al. (108) published the first report of PLV in adults with ARDS in 1996. Ten adult patients with severe ARDS requiring ECLS received PLV from 1 to 7 days. At 72 hrs after initiation of PLV, physiologic shunt decreased and static lung compliance improved. Instillation of PFC appeared safe, but no conclusions regarding efficacy can be drawn given the absence of a control group or a survival rate that did not differ from the predicted survival of 50%. In a similar study of pediatric patients with ARDS requiring ECLS, the same investigators found that PLV could be safely administered to children; again improvements in gas exchange and compliance were observed at 96 hrs (109). In 1998, Hirschl et al. (110) reported the results of a prospective, noncontrolled, phase I/II trial of PLV in adults with ARDS. Unlike the earlier report, the nine patients studied were not on ECLS, and effects of PLV on hemodynamics could be evaluated. During PLV, no significant changes occurred in the hemodynamic variables measured. The use of PLV did improve gas exchange as measured by reduced alveolar-arterial oxygen tension gradient, reduced FIO 2 , and increased mean venous oxygen saturation at 48 hrs. However, the improved gas exchange was not associated with improved pulmonary compliance as in earlier studies, and mortality remained near 50%. Because of the lack of control groups, these studies only constitute Level 4 evidence that PLV is useful in ALI/ARDS. As such, PLV can be given an E rating.
Fluid Management
There are several studies that support the concept that resuscitation to supranormal cardiac output and oxygen delivery improves outcome in critically ill patients (111-113). Patients with ALI/ ARDS are often in shock or have sepsis leading to a reduction in the effective circulating blood volume and inadequate oxygen delivery. Thus, correction of volume deficit and restoration of tissue oxygen delivery is a primary goal of therapy. A target pulmonary artery occlusion pressure (PAOP) of 14 -18 mm Hg has often been used because this occlusion pressure is commonly thought of as yielding an optimal cardiac output while minimizing the risk of hydrostatic pulmonary edema. If oxygen delivery is still inadequate after volume restoration with fluids or blood products, inotropic support is indicated. However, no study has demonstrated a benefit to supranormal oxygen delivery specifically in ARDS patients. Rather, the studies have been conducted in high-risk surgical or trauma patients. Furthermore, several recent studies provide evidence that therapy targeting supranormal values does not necessarily result in improved outcome (114 -116).
Several retrospective or small observational studies suggest that a strategy aimed at reduction of extravascular lung water (EVLW) will improve outcome in patients with ARDS (117-122). Bone (117) found that 10/12 patients with ARDS had significant improvement in gas exchange and pulmonary compliance after diuretics or dialysis. Costello et al. (122) found that four survivors of 11 patients with ARDS had the highest initial EVLW but also had the greatest reduction in lung water. These data do nothing to answer the questions of whether fluid therapy per se worsens outcome or whether sicker patients with a higher expected mortality receive more volume as part of their therapy.
The only prospective data to support this strategy comes from Schuster and coworkers, Mitchell et al. (123) and Schuller et al. (124) . They conducted a trial in 89 patients with pulmonary edema who required pulmonary artery catheterization. A total of 34 patients had congestive heart failure, whereas 48 had ARDS or sepsis. Seven patients did not have ARDS, sepsis, or congestive heart failure. Patients with ARDS (PAOP Ͻ18 torr) had a higher EVLW compared with those with congestive heart failure having a PAOP Ͼ18 torr (1326 Ϯ 774 mL vs. 1031 Ϯ 496 mL). A retrospective analysis of the data sorting by survival and treatment favored a therapeutic approach aimed at achieving a negative fluid balance (124). Survivors had no fluid gain or change in EVLW but a decreased PAOP compared with nonsurvivors. Patients with a net positive fluid gain Ͻ1 L in the first 36 hrs had an improved survival (74% vs. 50%) as well as a mean length of ventilation, ICU stay, and hospital stay that was one half that of patients who had a net fluid gain Ͼ1 L. Fluid balance was the only independent predictor of survival. Patients with ARDS that had a decrease in EVLW by Ͼ15% had decreased length of ventilation and ICU stay.
In the prospective study by Mitchell et al. (123), 52 patients were randomized to a group managed based on careful measurement of EVLW and 49 to a group managed based on PAOP measurements (123). The EVLW group was managed with a goal of using vasopressors in hypotensive, normovolemic patients and diuretics or vasodilators in normotensive patients. In the PAOP group, volume expansion was used in the hypotensive patient if the PAOP was Ͻ18 torr. Diuresis was avoided if the PAOP was Ͻ10 torr. In the patients managed by EVLW, the net fluid balance was 345 Ϯ 3350 vs. 2618 Ϯ 4178 in patients managed by PAOP. The EVLW was significantly lower in the EVLW management group compared with the PAOP group at every time point after 24 hrs. Despite no difference in survival, the time required for ventilation was 9 days in the EVLW group, as compared with 28 days for the PAOP group. Fluid restriction or diuresis was not associated with adverse effects on renal function or an increase in the number of days receiving vasopressors.
The above studies all indicate that careful clinical measurement of therapeutic endpoints is critical in the care of patients with ARDS. All of the patients in the study by Schuster's group (124) had a pulmonary artery catheter (PAC). Certainly, reliance on any one measure of intravascular volume status has flaws. Rather, a constellation of clinical indicators must be used to make a judgment about a patient's volume status. These variables may include systemic arterial pressure, central venous pressure, PAOP, cardiac output, urinary output, creatinine, acid-base status, and lactate level. This implies that patients with ARDS should be managed with a PAC. Given the recent controversy surrounding the PAC (125) and the lack of data to determine harm or benefit in patients with ARDS, PACs should be used only when measurement of these variables is likely to result in information that helps in making beneficial patient care decisions. Several trials are in various stages of design or completion and may yield interesting and useful data.
The data would support attempts to keep the pulmonary capillary pressure as low as possible in patients with ARDS while maintaining an adequate circulating blood volume, cardiac output, and oxygen delivery. Future studies should attempt to determine not only the best fluid management strategy but also the most clinically relevant monitoring strategy. At present, the data to support fluid restriction and/or diuretic therapy is grade 2 and the recommendation is C.
Surfactant
The first description of ARDS by Ashbaugh et al.
(1) included a notation of the similarities to neonatal respiratory distress syndrome, which results from a deficiency of surfactant. These early investigators hypothesized that surfactant deficiency may be a common mechanism of dysfunction. Several investigators have found surfactant dysfunction in animal models of ARDS (126 -128). Further, surfactant deficiency and dysfunction has been documented in human ARDS (126 --132). Ineffective surfactant may promote alveolar collapse in ARDS, thereby worsening compliance and increasing the need for positive pressure ventilation and higher inspired oxygen concentration. Surfactant may benefit patients with ARDS because of its surface tension lowering capability. Additionally, surfactant causes a dose-dependent reduction in proinflammatory cytokine production by human macrophages in vitro (133-136). Surfactant also inhibits superoxide production by human neutrophils by attenuation of translocation of cytosolic components of the respiratory burst oxidase to the plasma membrane (137-139).
Early nonrandomized trials of surfactant therapy report significant benefit in selected patients (140, 141). An early prospective, double-blind, placebo-controlled multicenter trial in 51 patients found that a synthetic surfactant failed to improve any physiologic variable (142). There was a dose-dependent trend in reduction of mortality from 47% in the placebo group to 41% and 35% in the surfactant treatment groups at 30 days that did not reach statistical significance. Reines et al. (143) studied 49 similar patients with ARDS using a higher dose of surfactant and found a more significant effect. However, synthetic surfactant failed to improve outcome in a follow-up study involving 725 patients with ARDS (144). In this study, there was no significant effect on hemodynamic variables, oxygenation, length of ventilation, length of ICU stay, or survival (60% for both groups at 30 days). There are several possible explanations for the lack of effect in this large multicenter trial. It may be attributable to the lack of an effect of surfactant in ARDS, an inadequate dose, an inadequate delivery system, an inappropriate preparation, or incorrect timing (144, 145).
Bovine surfactant has been studied in one randomized trial enrolling 59 patients (146). This trial was a pilot dose escalation study comparing the effect of 50 mg phospholipids/kg for 8 doses vs. 100 mg/kg for 4 doses vs. 100 mg/kg for 8 doses vs. a placebo group. A significant improvement in oxygenation was found in the 100 mg/kg ϫ 4 doses group at 120 hrs after initiation of treatment (FIO 2 , 40% vs. 55% in the placebo group and 65% in the 50 mg/kg group). Mortality at 28 days was 18.8% (100 mg/kg ϫ 4) and 16.6% (100 mg/kg ϫ 8) in the two higher dose treatment groups compared with 43.8% in the placebo group (p ϭ .075) and 50% in the lower dose surfactant group (50 mg/kg ϫ 8). These investigators went to great length to confirm that surfactant therapy actually had an effect on the composition of alveolar fluid. The fractional concentration of disaturated phosphatidylcholine increased significantly from 42.3% at baseline to 59.9% in the 100 mg/kg ϫ 4 group. The changes in the other treatment groups were similar but did not reach statistical significance compared with placebo. Surfactant instillation was generally well tolerated and caused no major safety concern.
From these studies one can conclude that there may be a role for surfactant therapy in ARDS. However, several questions need to be answered before determining its clinical role. These include the optimal dosage, delivery system, timing, and the actual preparation. Thus, surfactant cannot be recommended for routine use in ARDS at this time based on these data (Grade C based on Level 3 investigations).
Vasoactive Agonists
A hemodynamic feature of ALI/ARDS is pulmonary hypertension. This finding is so universal in ARDS that elevated pulmonary vascular resistance is considered an intrinsic part of the syndrome (14, 147-149). Resolution of the acute lung injury is accompanied by improvement in the pulmonary hypertension, whereas progressive pulmonary hypertension is associated with a poor outcome (14, 147-149). In the normal lung, both endothelium-derived nitric oxide (NO) and prostacyclin (PGI 2 ) are important in maintaining a low basal tone through stimulation of the adjacent smooth muscle soluble guanylate cyclase to produce cyclic guanosine monophosphate and adenylate cyclase to produce cyclic adenine monophosphate (cAMP) respectively (150 -152). Arterial hypoxemia in ARDS is mainly a result of an increase in the intrapulmonary shunt (153, 154). The pulmonary hypertension is multifactorial; it may be because of a combination of the injury itself, the inflammatory response to the injury, increased local and circulating levels of vasoconstrictive substances, thromboembolic disease, or iatrogenic factors, including ventilatory support (155). Net pulmonary vascular tone results from a balance of vasoconstriction and vasodilation (156). Deranged vasodilatory mechanisms may be inadequate to oppose the vasoconstriction caused by lung injury (157-160). Altered vasoreactivity may lead to alterations in the control of pulmonary blood flow distribution with a resultant increase in the intrapulmonary shunt and hypoxemia. Furthermore, pulmonary hypertension in concert with altered pulmonary vascular permeability contributes to pulmonary edema (161). Pulmonary hypertension may also lead to right ventricular dysfunction (162, 163). Intravenous vasodilators such as nitroprusside, nitroglycerin, prostaglandin E 1 (PGE 1 ), and PGI 2 effectively lower pulmonary artery pressure and vascular resistance (164 -168). However, their use is limited because their effects are not isolated to the pulmonary circulation; their use leads to systemic hypotension in up to 15% of patients. Furthermore, nonselective pulmonary vasodilation may cause an increase in the intrapulmonary shunt and worsening hypoxemia.
Nitric Oxide
The selective pulmonary vasodilatory effects of inhaled NO have been demonstrated in various models of acute lung injury including endotoxin, oleic acid, and smoke inhalation (169 -175) . Because NO is inhaled, it is an effective vasodilator of well-ventilated regions of the lung, thus reducing intrapulmonary shunt and improving arterial oxygenation. Furthermore, NO is rapidly bound to hemoglobin, which thereby inactivates it and prevents systemic vasodilation. Animal studies demonstrate that inhaled NO leads to a significant reduction in pulmonary artery pressure, improvement in ventilation-perfusion matching, and increased arterial oxygenation (170, 172, 173) . Furthermore, inhaled NO decreases pulmonary edema formation as assessed by lung wet to dry ratios and decreases neutrophil sequestration in the lung (172, 176, 177) .
Use of inhaled NO in human ARDS was first reported by Rossaint et al. (178) in the New England Journal of Medicine in 1993. This group of investigators compared the effects of inhaled NO at 18 and 36 ppm and the effect of intravenous prostacyclin at 4 ng/kg/min in nine patients with ARDS. Inhalation of NO resulted in reduction of the mean pulmonary artery pressure from 37 Ϯ 3 torr to 30 Ϯ 2 torr and decreased intrapulmonary shunting from 36% Ϯ 5% to 31% Ϯ 5%. This led to an increase in the PaO 2 / FIO 2 ratio from 152 Ϯ 15 torr to 199 
crease in intrapulmonary shunt, worsening oxygenation, and a decrease in the systemic arterial pressure. The patients were treated with inhaled NO for 3-53 days. Since this initial report, there have been numerous observational studies of inhaled NO in ARDS (178) .
Several recent trials of NO in ARDS have raised doubt that this therapy will lead to significant improvement in outcome (Table 5) . Dellinger et al. (179) recently reported the results of a doubleblind, randomized trial of NO vs. placebo in 177 patients with ARDS at 30 centers. An acute increase in PaO 2 was observed in 60% of patients receiving NO vs. 24% of placebo treated patients. This improvement in oxygenation resulted in a decrease in the intensity of mechanical ventilation over the first 4 days that was not sustained after that point. There were no differences between the groups in overall mortality, the number of days alive not receiving mechanical ventilation, or number of days alive meeting the oxygenation requirement for extubation.
Several other randomized studies of NO have similar results (180 -183) . A total of 40 patients were randomized at the University of Utah (182) . Inhaled NO, as compared with conventional ventilation, increased PaO 2 /FIO 2 ratio during the first 24 hrs; 60% of patients had an acute increase in PaO 2 with NO (response defined as an increase in PaO 2 /FIO 2 ratio of Ն20% or an absolute increase in the PaO 2 Ն10 torr). Other investigators have also found a variable response to inhaled NO (184, 185) . After 24 hrs, the two groups had an equivalent improvement in oxygenation (PaO 2 /FIO 2 ). NO did not increase the frequency of improved oxygenation (55% in NO group vs. 45% in conventional group) or the likelihood of persistent improvement in oxygenation, 63% vs. 50% (Fig. 2) . The European multicenter (43 sites) study enrolled 260 medical and surgical patients with ARDS (181) . In this trial, the mortality at 30 days was 45% for patients treated with NO vs. 38% for control patients. The mortality rate in patients not responding to NO was also 45% (response defined as PaO 2 Ͼ25% on any dose of NO). Similarly, the French phase III study of inhaled NO found no significant effect on survival (180) . Given the results of the above randomized trials (Level 1 evidence), NO cannot be recommended as a standard therapy for ARDS.
Almitrine
Almitrine bismesylate potentiates hypoxic pulmonary vasoconstriction leading to an improvement in ventilation perfusion matching and oxygenation (186, 187) . The effects of almitrine on pulmonary gas exchange and circulation has been assessed in two small series of patients with ARDS (187, 188) . In one series of nine patients, almitrine significantly increased PaO 2 from 78 Ϯ 15 torr to 140 Ϯ 49 torr. Alveolar-arterial oxygen tension gradient and shunt decreased during the administration of the drug. The multiple inert gas elimination technique showed that almitrine redistributed pulmonary blood flow from shunt areas to lung units with normal ventilation/perfusion ratios.
Several investigators have combined almitrine with inhaled NO (189 -192) . In one series of 17 patients, NO caused a modest, nonsignificant increase in the PaO 2 /FIO 2 ratio from 88 Ϯ 30 mm Hg to 98 Ϯ 37 mm Hg. The combination of NO and almitrine caused a significant increase in the PaO 2 /FIO 2 ratio from 92 Ϯ 25 mm Hg to 130 Ϯ 56 mm Hg. Seven patients were considered as "NO-responders." In this subgroup, the PaO 2 /FIO 2 ratio rose from 87 Ϯ 30 mm Hg to 128 Ϯ 39 mm Hg with NO alone, and from 93 Ϯ 20 mm Hg to 169 Ϯ 51 mm Hg (p ϭ .01) with combination therapy. Pulmonary artery pressure decreased with nitric oxide alone, whereas almitrine caused a nonsignificant increase in the mean pulmonary artery pressure from 28 Ϯ 5 mm Hg to 31 Ϯ 5 mm Hg. Combination therapy caused a significant decrease in the mean pulmonary artery pressure similar to inhaled NO alone. An additional approach has been to combine the prone position with almitrine and inhaled nitric oxide (193, 194) . Two series with a combination of 39 patients found that the combination of NO, prone position, and almitrine improved oxygenation to a greater degree than any single therapy or any combination of two of the therapies. Thus, it appears that almitrine improves oxygenation itself and increases the effects of inhaled nitric oxide. As its effects have only been determined in nonrandomized trials (Level 3 investigations), it can only be given a C recommendation.
Prostacyclin
In the original article on inhaled NO in the New England Journal of Medicine, Rossaint et al. (178) compared the effects of inhaled NO and an intravenous infusion of prostacyclin. Prostacyclin (PGI 2 ) reduced pulmonary artery pressure but increased intrapulmonary shunt and reduced the PaO 2 /FIO 2 ratio and systemic arterial pressure (178) . PGI 2 is synthesized in endothelial cells from arachidonic acid and is a potent vasodilator by a receptor-mediated increase in vascular smooth muscle cAMP (195) . Because most vasodilators' effects are not limited to the pulmonary circulation, systemic arterial hypotension is the usual cost of therapy. However, afterload reduction may improve systemic oxygen delivery and mixed venous oxygen content (165, 168, 196, 197) . As with inhaled NO, aerosolized administration of PGI 2 or PGE 1 may lead to vasodilation in well-ventilated areas of the lung (198 -202) . In fact, several direct comparisons of inhaled NO and prostacyclin reveal that the two agents have similar efficacy profiles (198 -200) . To date, no large, prospective, randomized trials have been done to define the role of inhaled prostacyclin in ARDS. As with almitrine, inhaled prostacyclin receives a C recommendation (Level 3 investigations).
Immune Modulating Strategies
Prostaglandin E 1 . PGE 1 engages the EP 2 receptor leading to activation of adenylate cyclase and an increase in intracellular cAMP. PGE 1 is an important regulator of neutrophil-and macrophagemediated inflammatory responses (203) (204) (205) (206) . Additionally, PGE 1 inhibits platelet aggregation and is a potent pulmonary vasodilator (164, 167, 207). Results of an early trial of infused PGE 1 in ARDS initially showed promise (168); however, these benefits were not confirmed in a larger multicenter investigation (196) .
Liposomes are spherical lipid bilayer structures up to 1 m in diameter that contain aqueous interiors. Liposomes are endogenously opsonized with C3bi and bind to the neutrophil CD11b/CD18 (CR3) receptor resulting in an increase in intracellular cAMP and subsequent downregulation of CD 18 surface receptor expression (208) . In animal studies, administration of liposomal encapsulated PGE 1 decreased edema and neutrophil sequestration in IL-1-induced ALI (209) . Further liposomal encapsulated PGE 1 improved survival in a rat endotoxin model even when given 16 hrs after the insult (208) .
In a phase II study, 25 patients with ARDS were prospectively randomized in an unbalanced ratio within each site to receive liposomal PGE 1 (n ϭ 17) or placebo (n ϭ 8). Improvement in PaO 2 /FIO 2 and compliance during the initial 8-day study period was greater in patients receiving liposomal PGE 1 (increase in PaO 2 / FIO 2 from baseline was 82.5 Ϯ 14.6 compared with placebo 28.3 Ϯ 22.1, p ϭ .05). On day 8, all eight patients given placebo required mechanical ventilation, and eight of 17 patients (47%) given liposomal PGE 1 were not receiving ventilation (p ϭ .03). The 28-day mortality rate was 6% (1/17 patients) in the liposomal PGE 1 group and 25% (2/8 patients) in the placebo group (p ϭ .23). However, a follow-up study of 348 patients failed to show efficacy (210) . Despite the finding that liposomal PGE 1 was associated with a shorter time to reach a PaO 2 /FIO 2 ratio Ͼ300, there was no difference in the length of time until patients did not require mechanical ventilation and no difference in 28-day mortality rate (PGE 1 32% vs. placebo 29%). Further, liposomal PGE 1 had an overall serious adverse event rate of 69% vs. 37% in the placebo group (with hypotension being the most frequent event). (210) . Given this negative data from a large, prospective, randomized trial, PGE 1 is not recommended for ARDS.
Ketoconazole. Thromboxane A 2 is a metabolite of arachidonic acid that is thought to be an important mediator in the pathogenesis of ALI/ARDS. Thromboxane A 2 synthesis and release is increased in both animal models of sepsis and ALI/ARDS, as well as in human sepsis and ARDS (211) (212) (213) (214) (215) (216) (217) (218) (219) . Thromboxane A 2 is a potent pulmonary vasoconstrictor and leads to an increase in platelet and neutrophil aggregation. Further, several animal studies have shown that thromboxane synthesis blockade or receptor antagonism ameliorates experimental lung injury (213, 214, 216 -219) . Ketoconazole is an imidazole used primarily as an antifungal agent but is also a potent and specific inhibitor of thromboxane synthetase. Ketoconazole significantly inhibits alveolar macrophage production of thromboxane. Additionally, ketoconazole inhibits 5-lipoxygenase, the enzyme responsible for the production of the neutrophil chemoattractant LTB4, and procoagulant activity, which may lead to pulmonary thromboembolic disease and contribute to pulmonary hypertension (220) .
The effect of cyclooxygenase blockade during sepsis has been studied in several trials of ibuprofen in sepsis. In a small pilot study of 30 patients with sepsis, treatment with ibuprofen led to improvements in gas exchange and airway mechanics (211) . Unfortunately, these favorable results were not confirmed in a follow-up study of 455 patients (212) . Treatment with ibuprofen did not reduce the incidence or duration of shock or ARDS and did not significantly improve the rate of survival at 30 days (mortality, 37% with ibuprofen vs. 40% with placebo).
Two small single-institution trials of ketoconazole therapy in patients at risk for ARDS suggested that it was effective at decreasing the risk in critically ill patients. Slotman et al. (221) studied 71 high-risk surgical patients and found a decrease in the incidence of ARDS (ketoconazole 6% vs. placebo 31%), reduced ICU length of stay and cost, and a nonsignificant reduction in mortality (31 vs. 42%). In the second trial, Yu and Tomasa (222) randomized 54 patients with sepsis within 24 hrs of ICU admission. The incidence of ARDS was significantly reduced in the ketoconazole group compared with placebo (15% vs. 64%). The mortality rate was also significantly lower in the ketoconazole group (15% vs. 39%). Although promising, the NIH ARDS Network did not confirm the results of these two studies in a larger multicenter trial of ketoconazole (223) . This trial enrolled 234 patients with ALI and ARDS from 10 centers. Despite bioavailability of ketoconazole, the study failed to show benefit on mortality, duration of ventilation, or any measure of lung function. On the basis of the quality of the evidence (Level 1 and 2) ketoconazole is not recommended for use in ARDS. Antioxidants. Reactive oxygen metabolites derived from neutrophils, macrophages, and endothelial cells are believed to be an important mechanism of cellular injury in the pathophysiology of ALI/ ARDS (5, 224 -227) . These oxidants include superoxide anion (O 2 Ϫ ), hydroxyl radical (OH⅐), hydrogen peroxide (H 2 O 2 ), and hypochlorous acid (HOCL) (228) . O 2 Ϫ is also capable of reacting with NO to form the highly reactive species peroxynitrite (ONOO -) (229) . Reactive oxygen metabolites cause injury through interactions with proteins, lipids, and DNA. An endogenous antioxidant system includes superoxide dismutase, catalase, glutathione, ␣ tocopherol (vitamin E), ascorbic acid (vitamin C), and sulfhydryls. Tissue damage through multiple mechanisms can occur through increased oxygen radical production or decreased antioxidants (230 -235) . Several strategies to prevent oxidant-mediated tissue injury have proven benefit in both in vitro and in vivo experiments (236 -241) . One strategy that may be useful is administration of N-acetylcysteine (NAC), which effectively increases cellular levels of one important antioxidant, reduced glutathione, through conversion to its precursor cysteine. Several animal studies have confirmed the ability of NAC to prevent oxidant-mediated injury (238 -241) .
Several small trials have examined the effect of NAC in patients with ALI/ARDS (Table 6 ). Jepsen et al. (242) found no effect of NAC on PaO 2 /FIO 2 or time to improvement of lung injury. NAC caused a small improvement in compliance that did not reach statistical significance (p ϭ .07). On the other hand, NAC had an effect on coagulation; the platelet count was significantly lower in the NAC group before and after treatment. There was a decrease in antithrombin III in the NAC group. The prothrombin time was significantly lower and the fibrinogen levels higher in the treatment group. Finally there was no difference in mortality (placebo, 50%; NAC, 53.1%) A second trial found that NAC improved the PaO 2 /FIO 2 ratio and lung injury severity score and decreased the need for mechanical ventilation; however, there was no difference in mortality (placebo 35% vs. NAC 22%) (243) .
In a third trial of NAC and another agent capable of increasing cellular glutathione, Procysteine, red blood cell glutathione gradually increased over the 10-day treatment period (244) . The number of acute lung injury-free days was increased in the procysteine group compared with both NAC and placebo. Cardiac index was increased in the groups receiving antioxidants (change in cardiac index, ϩ 14%) compared with placebo (Ϫ6%) (p Ͻ .05). Additionally, 73% of placebo patients developed a new organ failure in any organ vs. only 39% in combined treatment arms (p ϭ .057). However, mortality was no different among groups (placebo, 40%; NAC, 36%; procysteine, 35%) (244) . A fourth trial found that NAC failed to improve systemic oxygenation or reduce the need for ventilation (245) . A phase III trial of procysteine was stopped by an independent Safety Monitoring Board after 213 patients were enrolled because of a higher incidence of all-cause mortality in the treatment group compared with the patients receiving a placebo. Thus, the level of scientific evidence for NAC but not procysteine rises to level 2 (small randomized trials). However, given the mixed results of these trials, antioxidant therapy cannot be recommended at this time and procysteine is not recommended for ARDS.
Corticosteroids. The use of corticosteroids in sepsis and early ARDS to ameliorate the inflammatory response dates back to 1963 (246 There was no observed difference between groups in any study characteristic on entry or during the 5 days after entry. Additionally, there were no differences between the methylprednisolone and placebo groups in mortality (60% vs. 63% respectively; p ϭ .74) or in the reversal of ARDS (36% vs. 39%; p ϭ .77). Recent analysis of trials using glucocorticoids in sepsis and septic shock conclude that steroids do not improve and may actually worsen mortality in sepsis and septic shock (247, 250, 251) . Despite this unfavorable experience with steroids in sepsis and ARDS, there has been a recent resurgence in enthusiasm for their use in late ARDS (252) . Several small, uncontrolled series of steroids in late ARDS support this indication (253) (254) (255) (256) (257) (258) . In these collected series, 67 patients have been treated with various doses of steroids resulting in a high survival rate (76% to 83%). At the same time, complications appear to be a primary concern. Of the 67 treated patients, there were 27 major complications including sepsis, nosocomial pneumonia, wound infection and dehiscence, gastric rupture, and prolonged paralysis. Steroids may exert several beneficial effects in late progressive ARDS. Among these beneficial effects may be inhibition of activation of cytokine transcription factors (259, 260) and production of proinflammatory cytokines (261, 262) . In a study of 27 patients with ARDS, Meduri et al. (262) found that higher plasma levels of TNF-␣, IL-1 ␤, IL-6, and IL-8 on day 1 of ARDS and persistent elevation of these inflammatory cytokines over time were associated with nonsurvival. On the other hand, survivors of ARDS had lesser elevations of plasma inflammatory cytokines on day 1 and a rapid reduction over time. These same investigators then examined the effect of glucocorticoids on both serum and bronchoalveolar lavage (BAL) concentration of proinflammatory cytokines as well as improvements in the Murray LIS, indices of endothelial permeability, and final outcome. Five patients had a rapid improvement in LIS; whereas two patients had a delayed response and two patients had no response. After initiation of treatment, significant reductions in plasma TNF-␣ and IL-6 levels were seen by day 7 in both rapid and delayed responders. IL-1␤ was significantly reduced by day 5 in rapid responders and by day 10 in delayed responders. In responders, improvement in LIS paralleled reduction in plasma and BAL cytokine levels.
Steroids also prevent excessive collagen deposition and increase collagen breakdown (263) . The late phase of ARDS is characterized by progressive pulmonary fibrosis and lung restriction (5, 264 -267) . Increased levels of type III procollagen, a useful biological marker of collagen synthesis, are frequently detected in the BAL fluid from patients with ARDS and are strongly associated with increased risk of nonsurvival (264) . There is evidence that steroids may interfere with this fibroproliferative process. Meduri (261, 267) investigated 29 patients with ARDS by serial measurement of plasma and BAL procollagen aminoterminal propeptide type I (PINP) and type III (PIIINP) levels as well as the LIS and multiple organ dysfunction score. Patients were divided into responders if there was a reduction in LIS during the first week of therapy with methylprednisolone (improvers, 7; nonimprovers, 22). On day 1 of ARDS, plasma PINP or PIIINP levels were elevated in all patients. By day 7, mean plasma PINP or PIIINP levels were unchanged in responders but increased significantly in nonsurvivors. On day 7, patients with plasma PINP levels Ͻ100 ng/mL were 2.5 times more likely to survive, and patients with plasma PIIINP levels Ͼ25 ng/mL were nine times more likely to die. Patients taking placebo had no change in plasma PINP or PIIINP levels over time, whereas patients treated with methylprednisolone (n ϭ 11) had a rapid and sustained reduction in mean plasma and BAL PINP and PIIINP levels. Steroids led to an improved PaO 2 /FIO 2 ratio, resulting in a decrease in the level of positive endexpiratory pressure used for ventilation. In addition to these beneficial effects of steroids on lung physiology, creatinine, bilirubin, and temperature also decreased.
The only randomized trial of steroids for late ARDS was conducted by Meduri et al. (268) . A total of 24 patients with ARDS who failed to improve by day 7 were randomized (steroid:placebo ratio, 2:1) to receive placebo or methylprednisolone every 6 hrs (2 mg/kg load followed by 2 mg/kg/day for 2 wks followed by tapering to 1 mg/kg/day, 0.5 mg/kg/day, and 0.125 mg/kg/day on a weekly basis). Four patients failing to improve after 10 days of treatment were blindly crossed over to the alternative treatment. All four of these patients were originally in the placebo group. Patients underwent an extensive evaluation for infectious morbidity. Methylprednisolone resulted in an improvement in LIS, improved PaO 2 /FIO 2 ratio (262 Ϯ 19 vs. 148 Ϯ 35, p Ͻ .001); decreased multiple organ dysfunction score, and successful extubation (7 vs. 0; p ϭ .05). ICU mortality was 0 (0%) of 16 vs. 5 (62%) of 8 (p ϭ .002) and hospitalassociated mortality was 2 (12%) of 16 vs. 5 (62%) of 8 (p ϭ .03) for steroids vs. placebo. The rate of infections per day of treatment was similar in both groups. The infection rate ratio per day of mechanical ventilation for methylprednisolone compared with placebo was 1.80 (95% confidence interval, 0.86 -3.76); 75% of patients in each arm developed a new infection. Also, 31% of treatment patients developed new hyperglycemia, compared with 50% of placebo patients.
The Meduri et al. trial (268) provides limited evidence that steroids may be beneficial in late phase ARDS (Level 2 investigation). However, there are several methodologic concerns with that trial, including the crossover design of this trial. Results from the NIH ARDS Network Late Steroid Rescue Study may help to define the exact role of steroids in this disease (269) . Until the results of the NIH ARDS Network trial are available, corticosteroids are given a C recommendation (level 2 data).
CONCLUSIONS
Clinicians caring for patients with ARDS have long recognized that only a small number of patients (5%) die as a result of respiratory failure. Instead, the majority of deaths occur because of progressive multiple organ failure or sepsis. Because several of the therapies examined in this review, such as inhaled NO or liposomal PGE 1 , only lead to a transient improvement in oxygenation, it is unlikely that they will be demonstrated to make a significant improvement in outcome.
There may be several reasons some of the therapies examined had no effect on outcome. First, the therapy may have no effect on ARDS; second, drug dosage, timing, and route may have been inappropriate; third; the endpoints examined may have been too crude a measure of outcome; and last, the conduct of the clinical trial may not have been strict enough to ensure uniform treatment and expected outcome. Changes in outcome that have occurred over the years (12) are likely attributable to several factors, including improved ventilator management, sophisticated monitoring devices, fluid management, nutrition support, and antibiotic therapy.
As with the sepsis trials, selection of patients for an ARDS trial may be a crucial factor (270) . The definition of ALI/ ARDS is based on symptoms and signs (3). This fact leads to a heterogeneous population of patients entered into a clinical trial. The etiology of ALI/ARDS may have an important influence on outcome. Stratification of patients according to risk factor, such as a multiple system trauma patient vs. a patient with ARDS resulting from pneumonia, may lead to a more biologically sound treatment approach. Second, mortality may not be an appro-priate end point in ARDS trials (55, 271). Mortality from death in ARDS is attributable to multiple factors, including the underlying disease process and the high incidence of coexisting multiple organ failure. Surrogate end points such as improvement in pulmonary physiology or reduction in morbidity and cost may reveal therapies that do not impact on mortality yet have clinical value.
New developments continue to reveal significant understanding about the inflammatory response and the pathogenesis of ARDS. Future directions in treatment modalities may include combination of some of the above therapies. Alternative new intervention strategies may arise such as high-frequency ventilation (272), lung recruitment maneuvers, ␤-2-adrenergic stimulation (273, 274) , protein kinase inhibition, (275) phosphatidic acid generation inhibition (276, 277) , antagonism of neutrophilendothelium adhesion (278 -280) , complement inhibition (281, 282) , IL-10 (283), and elastase inhibition (284, 285) . Alternatively, a fundamental flaw in the past therapeutic strategies may be in not accounting for the heterogeneity of patients with ARDS. The best future strategies may arise from identifying patient subgroups with similar pathophysiologic and biochemical mechanisms of disease who may then respond to appropriately directed therapy to fight their specific disease process. 
